新光药业
(300519)
| 流通市值：16.42亿 | | | 总市值：23.02亿 |
| 流通股本：1.14亿 | | | 总股本：1.60亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 210,958,037 | 142,593,090.09 | 88,469,330.56 | 265,359,823.7 |
| 营业收入 | 210,958,037 | 142,593,090.09 | 88,469,330.56 | 265,359,823.7 |
| 二、营业总成本 | 141,623,596.13 | 101,939,916.61 | 59,792,683.17 | 208,296,602.07 |
| 营业成本 | 104,873,442.29 | 76,909,189.87 | 48,334,866.13 | 162,503,315.71 |
| 税金及附加 | 4,035,116.43 | 2,717,145.03 | 1,567,560.49 | 5,095,515.06 |
| 销售费用 | 11,525,079.11 | 8,003,618.87 | 4,124,410.42 | 20,098,115.72 |
| 管理费用 | 12,960,463.87 | 8,674,594.45 | 3,915,917.36 | 18,363,756.82 |
| 研发费用 | 9,695,792.68 | 6,879,581.55 | 2,826,423.66 | 13,349,594.41 |
| 财务费用 | -1,466,298.25 | -1,244,213.16 | -976,494.89 | -11,113,695.65 |
| 其中:利息收入 | 1,475,604.61 | 1,250,846.19 | 979,497.89 | 11,125,953.79 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 4,204,120.02 | 3,539,533.05 | 999,576.46 | 5,630,250.11 |
| 资产处置收益 | 98,545.51 | - | - | -3,722.27 |
| 资产减值损失(新) | 146,611.95 | 236,649.38 | 103,348.75 | -435,419.57 |
| 信用减值损失(新) | -320,267.32 | -25,225.94 | 163,550.4 | 202,874.74 |
| 其他收益 | 1,313,663.71 | 994,486.3 | 524,748.49 | 2,407,058 |
| 四、营业利润 | 74,777,114.74 | 45,398,616.27 | 30,467,871.49 | 64,864,262.64 |
| 加:营业外收入 | 57,571.73 | 57,571.73 | - | 334,427.08 |
| 减:营业外支出 | 1,071,370 | - | - | 1,771,616.74 |
| 五、利润总额 | 73,763,316.47 | 45,456,188 | 30,467,871.49 | 63,427,072.98 |
| 减:所得税费用 | 9,663,155.41 | 5,744,115.54 | 4,099,896.15 | 9,215,614.46 |
| 六、净利润 | 64,100,161.06 | 39,712,072.46 | 26,367,975.34 | 54,211,458.52 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 64,100,161.06 | 39,712,072.46 | 26,367,975.34 | 54,211,458.52 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 64,100,161.06 | 39,712,072.46 | 26,367,975.34 | 54,211,458.52 |
| 扣除非经常损益后的净利润 | 60,648,831.8 | 36,209,446.74 | 25,238,534.55 | 49,592,104.44 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.25 | 0.16 | 0.34 |
| (二)稀释每股收益 | 0.4 | 0.25 | 0.16 | 0.34 |
| 八、其他综合收益 | -225,778.44 | -866,110.88 | -122,750.41 | 67,953.34 |
| 归属于母公司股东的其他综合收益 | -225,778.44 | -866,110.88 | -122,750.41 | 67,953.34 |
| 九、综合收益总额 | 63,874,382.62 | 38,845,961.58 | 26,245,224.93 | 54,279,411.86 |
| 归属于母公司股东的综合收益总额 | 63,874,382.62 | 38,845,961.58 | 26,245,224.93 | 54,279,411.86 |
| 公告日期 | 2026-10-23 | 2026-08-25 | 2026-04-21 | 2026-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |